16.05.2007 13:00:00

Lumera Announces Next Podcast Installment; Interview with Dr. Larry Dalton Next in 2007 Lumera Experts Series

Lumera Corporation (NASDAQ: LMRA), a leader in the emerging field of nanotechnology, announced today its next installment of its 2007 Lumera Experts Podcasting Series. The featured interview is with Dr. Larry Dalton a global electro-optic expert and Nobel Prize Nominee and Professor of Chemistry and Electrical engineering at the University of Washington. Dr. Dalton, a distinguished professor and a global expert in photonics and electro-optics has received numerous awards for pioneering many breakthroughs in electro-optic polymer technology including the technology that is the foundation for Lumera’s Electro-Optic Polymer Modulator. "Electro-optics and photonics have an enormous impact on our lives, but we all take them for granted,” said Dalton in his podcast interview. "In the future electro-optic technology could play a critical role in next generation defense, computer transportation, medicine, entertainment, information technology and energy.” "As a company committed to fabricating high-performance and cost-effective polymers we feel fortunate to have Larry Dalton, whose research is greatly contributing to the future of photonics and electro-optics, as a business partner,” commented Lumera Chief Executive Officer Tom Mino. "Companies like Lumera are playing critical roles in getting federally sponsored, university generated technologies to the marketplace,” continued Dalton. "Lumera is solving a lot of problems associated with device design and fabrication, particularly with polymers being used in fiber-optic transmission, to help get these types of products to market.” Earlier this year, Lumera announced the 2007 Lumera Experts Podcast Series featuring interviews with industry leaders who are familiar with Lumera’s technology and are experts in nanotechnology, bio-arrays, drug discovery, electro-optics, and wireless technologies. Dr. Niro Ramachandran, a research associate at the Harvard Institute of Proteomics led by Dr. Josh LaBaer, was the first interview featured and the podcast is currently available to download on Lumera’s website. The podcasts are available through a variety of distribution networks and can be downloaded among other places at podtech.com; Apple’s iTunes, Rocky Mountain Podcasting and at Lumera’s own website, http://www.lumera.com/Company/Podcasts.php. About Lumera Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com. Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.

Nachrichten zu GigOptix Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu GigOptix Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!